A potential role for T H 17 cells has been suggested in a number of conditions including neurodevelopmental disorders such as autism spectrum disorders (ASD). In the current study, we investigated cellular release of IL-17 and IL-23 following an in-vitro immunological challenge of peripheral blood mononuclear cells (PBMC) from children with ASD compared to age-matched typically developing controls. Following stimulation, the concentration of IL-23, but not IL-17, was significantly reduced (p = 0.021) in ASD compared to controls. Decreased cellular IL-23 production in ASD warrants further research to determine its role on the generation and survival of T H 17 cells, a cell subset important in neuroinflammatory conditions that may include ASD.
Introduction
Autism spectrum disorders (ASD) are neurodevelopmental disorders characterized by severe impairments in social interaction and communication, and restricted, stereotyped interests (American Psychiatric Association, 1994) . Symptoms of ASD generally manifest within the first three years of life and persist through adulthood in most cases. Evidence of immune dysregulation has been observed in some individuals with ASD, including increased levels of pro-inflammatory cytokines in brain tissues, CSF and plasma, and increased production of pro-inflammatory cytokines by peripheral blood mononuclear cell (PBMC) cultures when compared to typically developing controls (Ashwood et al., 2008; Ashwood and Wakefield, 2006; Enstrom et al., 2009a; Jyonouchi et al., 2001; Molloy et al., 2006; Vargas et al., 2005; Zimmerman et al., 2005) .
Recently, T H 17 cells (Bettelli et al., 2007) were described as a subset of T cells unique for their production of interleukin (IL)-17, a cytokine demonstrated to be important for defense against extracellular bacteria (Raffatellu et al., 2008; Tato and O'Shea, 2006) , fungi (Taylor et al., 2007) , and specific parasites (Reece et al., 2008) . In addition, these cells have been implicated in the pathology of a number of inflammatory conditions including multiple sclerosis (MS), rheumatoid arthritis, Crohn's disease, and psoriasis (Graber et al., 2008; Tzartos et al., 2008; Vaknin-Dembinsky et al., 2008) . As a survival and proliferative factor for T H 17 cells, IL-23 promotes sustained production of IL-17 by T H 17 cells (Aggarwal et al., 2003) . In animal models, anti-IL-23 therapy can ameliorate experimental autoimmune encephalomyelitis (EAE) (Chen et al., 2006) , suggesting that dysregulation of T H 17 cells may contribute to disorders with suspected autoimmune/neuroinflammatory mechanisms, such as ASD.
Dysregulated immune responses in some individuals with ASD could lead to the aberrant production of IL-23 from immune cells. We recently reported that plasma IL-23 levels were decreased in ASD children (Enstrom et al., 2008) . To help elucidate whether there exists a potential dysregulation of IL-23 and IL-17 production in ASD, we examined the effect of immune stimulation of PBMC isolated from children with ASD and typically developing controls in the same age range.
Materials and methods
Ninety-four subjects were recruited as part of the Childhood Autism Risks from Genetics and Environment (CHARGE) study (Hertz-Picciotto et al., 2006) . For the experiments involving phytohemagglutinin (PHA) Journal of Neuroimmunology 216 (2009) 126-129 
